PURPOSE: To assess the role of "melanoma inhibitory activity" (MIA) as a potential serum marker for screening and detection of metastatic uveal melanoma. DESIGN: Prospective, clinical study. MATERIAL AND METHODS: Serum samples of 305 patients with uveal melanoma were collected. Serum samples were analysed by a one-step enzyme-linked immunosorbent assay (ELISA) to quantify the MIA serum levels. All patients underwent a standardized echography of the globe to evaluate maximum tumour height and were checked for systemic metastasis of the tumour by liver enzyme tests and ultrasonography of the liver. RESULTS: Twenty patients (6.6%) had proven metastatic disease; eight of them developed it during follow-up. The mean serum concentration of MIA in the 285 patients without metastasis was 6.72 ng/ml, whereas the mean serum concentration of MIA in the 20 patients with metastasis was 13.03 ng/ml (P<0.001). The eight patients who developed metastatic disease during follow-up showed an MIA of 5.92 ng/ml before detection of metastasis and 12.21 ng/ml afterwards (P<0.001). MIA serum levels did neither correlate with the tumour height or to whether local therapy had been applied. CONCLUSION: The elevation of MIA serum levels in patients with metastatic disease from melanoma supports its promising role as a serum marker for monitoring patients with uveal melanoma.
PURPOSE: To assess the role of "melanoma inhibitory activity" (MIA) as a potential serum marker for screening and detection of metastatic uveal melanoma. DESIGN: Prospective, clinical study. MATERIAL AND METHODS: Serum samples of 305 patients with uveal melanoma were collected. Serum samples were analysed by a one-step enzyme-linked immunosorbent assay (ELISA) to quantify the MIA serum levels. All patients underwent a standardized echography of the globe to evaluate maximum tumour height and were checked for systemic metastasis of the tumour by liver enzyme tests and ultrasonography of the liver. RESULTS: Twenty patients (6.6%) had proven metastatic disease; eight of them developed it during follow-up. The mean serum concentration of MIA in the 285 patients without metastasis was 6.72 ng/ml, whereas the mean serum concentration of MIA in the 20 patients with metastasis was 13.03 ng/ml (P<0.001). The eight patients who developed metastatic disease during follow-up showed an MIA of 5.92 ng/ml before detection of metastasis and 12.21 ng/ml afterwards (P<0.001). MIA serum levels did neither correlate with the tumour height or to whether local therapy had been applied. CONCLUSION: The elevation of MIA serum levels in patients with metastatic disease from melanoma supports its promising role as a serum marker for monitoring patients with uveal melanoma.
Authors: Marie Diener-West; Sandra M Reynolds; Donna J Agugliaro; Robert Caldwell; Kristi Cumming; John D Earle; Donna L Green; Barbara S Hawkins; James Hayman; Ishmael Jaiyesimi; John M Kirkwood; Wui-Jin Koh; Dennis M Robertson; John M Shaw; Jonni Thoma Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: J Kan-Mitchell; P E Liggett; C R Taylor; N Rao; E S Granada; K D Danenberg; W L White; L J Van Eldik; T Horikoshi; P V Danenberg Journal: Invest Ophthalmol Vis Sci Date: 1993-11 Impact factor: 4.799
Authors: Daniela Suesskind; Andreas Schatz; Sven Schnichels; Sarah E Coupland; Sarah L Lake; Bernd Wissinger; Karl U Bartz-Schmidt; Sigrid Henke-Fahle Journal: Graefes Arch Clin Exp Ophthalmol Date: 2011-09-01 Impact factor: 3.117
Authors: Martina Angi; Helen Kalirai; Samuel Prendergast; Deborah Simpson; Dean E Hammond; Michele C Madigan; Robert J Beynon; Sarah E Coupland Journal: Oncotarget Date: 2016-08-02
Authors: Manuel F Bande Rodríguez; Beatriz Fernandez Marta; Nerea Lago Baameiro; Maria Santiago-Varela; Paula Silva-Rodríguez; María Jose Blanco-Teijeiro; Maria Pardo Perez; Antonio Piñeiro Ces Journal: Clin Ophthalmol Date: 2020-01-20
Authors: Miguel A Ortega; Oscar Fraile-Martínez; Natalio García-Honduvilla; Santiago Coca; Melchor Álvarez-Mon; Julia Buján; Miguel A Teus Journal: Int J Oncol Date: 2020-10-22 Impact factor: 5.650